MASHYA ABBASSİ, ROGER RİLEY, MARK MALKİN, YANG TANG, BİPİN RAJENDRAN, VİCTOR YAZBECK
Experimental and Clinical Transplantation - 2019;17(1):111-114
Posttransplant lymphoproliferative disorder is a serious complication of solid-organ transplant. Extranodal involvement is common; however, isolated involvement of the central nervous system is extremely rare and represents a particularly difficult therapeutic challenge with no current consensus on optimal treatment. Here, we describe a 70-year-old woman who developed Epstein-Barr virus-related primary central nervous system lymphoma 19 months after kidney transplant. Immunosuppression was reduced, and the patient was started on high-dose methotrexate, which was complicated by acute kidney injury and discontinued. She then received a rituximab and temozolomide chemotherapeutic regimen and achieved complete clinical response. Seventeen months after diagnosis, she is alive and has not developed any other posttransplant lymphopro - liferative disorder. We review the current literature and discuss treatment options for patients with primary central nervous system posttransplant lymphopro - liferative disorder following kidney transplant.
